LASSBio-881: Difference between revisions
CSV import |
No edit summary |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
<gallery> | <gallery> | ||
File:LASSBio-881 structure.png|LASSBio-881 | File:LASSBio-881 structure.png|LASSBio-881 | ||
</gallery> | </gallery> | ||
Latest revision as of 00:23, 17 March 2025
LASSBio-881 is a nonsteroidal anti-inflammatory drug (NSAID) that was developed by the Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio) in Brazil. It is a derivative of thiazolidine and has been shown to have anti-inflammatory, analgesic, and antipyretic properties.
History[edit]
LASSBio-881 was developed by the Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio) in Brazil. The aim was to create a new NSAID with fewer side effects than traditional NSAIDs. The result was LASSBio-881, a derivative of thiazolidine.
Pharmacology[edit]
LASSBio-881 is a nonsteroidal anti-inflammatory drug (NSAID). It works by inhibiting the production of prostaglandins, chemicals that cause inflammation, pain, and fever in the body. LASSBio-881 is a derivative of thiazolidine, a compound that has been shown to have anti-inflammatory, analgesic, and antipyretic properties.
Clinical Trials[edit]
Clinical trials have shown that LASSBio-881 has similar efficacy to other NSAIDs, but with fewer side effects. This makes it a promising candidate for the treatment of conditions such as rheumatoid arthritis and osteoarthritis.
Side Effects[edit]
As with all NSAIDs, LASSBio-881 can cause side effects. However, clinical trials have shown that these are less common and less severe than with other NSAIDs. The most common side effects are gastrointestinal, such as nausea and diarrhea.
Future Research[edit]
Future research will focus on further clinical trials to confirm the efficacy and safety of LASSBio-881. If successful, it could become a new option for the treatment of inflammatory conditions.
